Bionomics Ltd B1N-FF:Frankfurt Stock Exchange

RT Quote | Exchange | EUR
Last | 8:20 AM CEST
0.0348quote price arrow down-0.002 (-5.43%)
52 week range
0.03 - 0.15
Loading...
  • Open0.0348
  • Day High0.0348
  • Day Low0.0348
  • Prev Close0.04
  • 52 Week High0.15
  • 52 Week High Date06/17/21
  • 52 Week Low0.03
  • 52 Week Low Date05/18/22

Key Stats

  • Market Cap58.6M
  • Shares Out1,309.56M
  • 10 Day Average Volume21,660.8
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-44.05

KEY STATS

  • Open0.0348
  • Day High0.0348
  • Day Low0.0348
  • Prev Close0.04
  • 52 Week High0.15
  • 52 Week High Date06/17/21
  • 52 Week Low0.03
  • 52 Week Low Date05/18/22
  • Market Cap58.6M
  • Shares Out1,309.56M
  • 10 Day Average Volume21,660.8
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-44.05

RATIOS/PROFITABILITY

  • EPS (TTM)-0.02
  • P/E (TTM)-1.74
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-
  • ROE (TTM)-
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Bionomics Ltd

There is no recent news for this security.

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
Bionomics Limited (Bionomics) is an Australia-bases clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of novel, ion channel targeting drug candidates designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders. The Company operates in drug development segment in Australia. The Company is advancing its lead drug candidate, BNC210, which is an oral, proprietary, selective negative allosteric...
Errol De Souza Ph.D.
Executive Chairman of the Board
Adrian Hinton
Acting Chief Financial Officer
Connor Bernstein
Vice President Strategy and Corporate Development
Liz Doolin
Vice President Clinical Development
Address
200 Greenhill Road
Thebarton, SA
5063
Australia